Vesicor Therapeutics

Executive Summary

Vesicor Therapeutics is a preclinical-stage biotechnology company pioneering a non-viral, immune-silent delivery platform for gene therapies targeting cancer. The company's proprietary microvesicle technology enables precise delivery of therapeutic mRNA directly to tumor cells, avoiding the immunogenicity and toxicities associated with viral vectors. Its lead candidate, VSC-101, delivers p53 mRNA to restore tumor suppression in p53-deficient cancers. Founded in 2021 and based in San Diego, CA, Vesicor addresses a major challenge in oncology: safe and effective delivery of tumor suppressor genes. The platform's potential extends beyond p53, offering a versatile approach for multiple cancer indications. While still in early development, the company's innovative strategy positions it as a emerging player in the non-viral gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026IND-Enabling Studies Completion for VSC-10170% success
• Q2 2026Series A Financing Round60% success
• Q4 2026In Vivo Proof-of-Concept Data Release50% success